BTG shares gain on solid interims while Interserve slumps for second day in a row
A look at the day's gainers and painers, including Vodafone, FirstGroup and Haydale Graphene
Company
Sareum Holdings PLC
LON:SAR
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer. The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development.
239 stories · page 6 of 12
Investments and investor services
FTSE 100 flatlines at close as sterling gains on Brexit optimism
The UK blue-chip benchmark closed up 0.68 at 7,053, while the FTSE 250 added over 174 points at 18,985
Preliminary results from Sierra Oncology’s clinical trials of Sareum’s SRA737 compound due in H1 2019
US firm Sierra Oncology, which is the licence holder of SRA737, said in its quarterly update, it has made “substantial progress” with its two clinical development programmes for the compound
Archive
Proactive news snapshot: Immotion Group, NetScientific, AdEPT Technology …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: Metal Tiger, Bacanora Lithium, Redx Pharma …
A glance at some of the day's highlights from the Proactive Investors newswire
Cold weather in Nevada means Great Western Mining may have to suspend drilling until March
A look at some of the main news-driven risers and fallers in London on Friday ...
Sareum secures funding for drug programme
The company has raised £850,000 before expenses, which will be used to develop potential treatments for cancer and autoimmune diseases
FTSE 100 closes off lows but shoulders drop as US stocks plunge with tech disappointments
At the close, the UK blue-chip index was down 64.54 points, or 0.9% at 6,939.56, albeit bouncing off the hefty session low of 6,851.59 having spent all day heavily in the red
Archive
Proactive news snapshot: Greatland Gold, European Metals, Chesnara, BigDish...
A glance at some of the day's highlights from the Proactive Investors newswire
Sareum makes strong progress on cancer and autoimmune disease therapies
Sareum said it would continue talks with potential licence partners for its therapies under development
Archive
Proactive news snapshot: Amryt Pharma, Directa Plus, Live Company...
A glance at some of the day's highlights from the Proactive Investors newswire
Sareum selects potential anti-cancer molecule for further development
Sareum has now chosen two molecules from its TYK2 inhibitor programme for further development, one as a potential treatment for autoimmune disease and the other for certain types of cancer
Archive
Proactive news snapshot: IXICO, Mkango Resources, Diversified Gas & Oil …
A glance at some of the day's highlights from the Proactive Investors newswire
Alumasc shares advance as it is 'well positioned' to outperform UK construction market
A look at some of the top risers and fallers in London on Tuesday
Sareum reports “strong progress” made with in-house and out-licensed drug programmes
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
FTSE 100 stays in red at close as Brexit deal confidence wanes; trade fears persist
The UK bluechip index fell 25 points to 7,253 around 3.50pm
Archive
Proactive news snapshot: Savannah Resources, Rockfire Resources, OptiBiotix Health …
A glance at some of the day's highlights from the Proactive Investors newswire
UK Oil & Gas rallies after completing Portland reservoir test at Horse Hill
A look at some of the top risers and fallers in London on Monday